Curran Simpson - 31 Dec 2025 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: RGNX
Reported as of: 31 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jul 2026, 16:51:42 UTC
Prior SEC filing: 10 Oct 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Patrick J. Christmas as attorney-in-fact

Key filing fact

Curran Simpson filed Form 4 for REGENXBIO Inc. (RGNX) on 06 Jul 2026.

Key facts

This page summarizes Curran Simpson's Form 4 filing for REGENXBIO Inc. (RGNX).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 06 Jul 2026, 16:51.

Change

Previous filing in this sequence was filed on 10 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001346164 Primary reporting owner

Simpson Curran

Relationship: Chief Executive Officer, Director
Address: C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE
Signature: /s/ Patrick J. Christmas as attorney-in-fact
Signature date: 06 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGNX transaction

Common Stock

Award

Transaction value
Shares: +951
Change %: +0.28%
Price: $7.00^*
Shares after: 343,418
Date: 31 Dec 2025
Ownership: Direct
Footnotes: F1, F2

RGNX transaction

Common Stock

Award

Transaction value
Shares: +1,453
Change %: +0.42%
Price: $10.18^*
Shares after: 344,871
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F3, F4

RGNX transaction

Common Stock

Tax liability

Transaction value
Shares: -6,818
Change %: -2%
Price: $13.09^*
Shares after: 338,053
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is exempt under Rule 16b-3(c).

Footnote F2

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025.

Footnote F3

The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is exempt under Rule 16b-3(c).

Footnote F4

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2026.

Footnote F5

Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on July 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on July 1, 2026.